Simulation analysis of EGFR mutation detection: Oncomine Dx target test and AmoyDx panel impact on lung cancer treatment decisions
Y Hirotsu, T Nakagomi, Y Nagakubo, T Goto… - Scientific Reports, 2024 - nature.com
Lung cancer is a leading cause of cancer-related deaths worldwide. Epidermal growth factor
receptor (EGFR) driver mutations are crucial for treatment decisions for patients with non …
receptor (EGFR) driver mutations are crucial for treatment decisions for patients with non …
[HTML][HTML] The differential prognostic implications of PD-L1 expression in the outcomes of Filipinos with EGFR-mutant NSCLC treated with tyrosine kinase inhibitors
HGC Luna, MS Imasa, N Juat… - Translational Lung …, 2023 - ncbi.nlm.nih.gov
Background The tumor immune microenvironment influences tumor evolution in non-small
cell lung cancer (NSCLC). Yet, the prognostic value of programmed death-ligand 1 (PD-L1) …
cell lung cancer (NSCLC). Yet, the prognostic value of programmed death-ligand 1 (PD-L1) …
Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real‐world cohort analysis
Y Sun, S Qin, S Wang, J Pang, Q Ou… - The Journal of …, 2024 - Wiley Online Library
Pulmonary spindle cell carcinoma (PSCC) is a rare and aggressive non‐small cell lung
cancer (NSCLC) subtype with a dismal prognosis. The molecular characteristics of PSCC …
cancer (NSCLC) subtype with a dismal prognosis. The molecular characteristics of PSCC …
Clinicopathological and prognostic implications of EGFR mutations subtypes in Moroccan non-small cell lung cancer patients: A first report
S Boukansa, I Mouhrach, F El Agy, S El Bardai… - Plos one, 2024 - journals.plos.org
Background Non-small cell lung cancer (NSCLC) remains a significant global health
concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This …
concern, with EGFR mutations playing a pivotal role in guiding treatment decisions. This …
An epidermal growth factor receptor compound mutation of L858R with S768I in advanced non-small-cell lung cancer: a case report
S Boukansa, I Mouhrach, F El Agy… - Journal of Medical Case …, 2024 - Springer
Background In the current treatment landscape for non-small cell lung cancers, epidermal
growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established …
growth factor receptor-tyrosine kinase inhibitors have emerged as a well-established …